Juan C., Zamorano L., Perez J.L., Ge Y., Oliver A. Multidrugresistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Magiorakos A.P., Srinivasan A., Carey R.B., et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Tumbarello M., De Pascale G., Trecarichi E.M., et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Micek S.T., Wunderink R.G., Kollef M.H., et al.
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Tumbarello M., Repetto E., Trecarichi E.M., et al.
Increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa as compared to other bacteria: Results of a 13-year prospective cohort study. Thaden J.T., Park L.P., Maskarinec S.A., et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Pena C., Cabot G., Gomez-Zorrilla S., et al. Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of Pseudomonas aeruginosa Bacteremia. Morata L., Cobos-Trigueros N., MartÃnez J.A., et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Siegman-Igra Y., Ravona R., Primerman H., Giladi M. Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Influence of Delayed Receipt of Effective Antimicrobial Therapy on Clinical Outcome. Clinical Significance and Predictors of Community-Onset Pseudomonas aeruginosa Bacteremia. Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. AMRmap: an online platform for monitoring antibiotic resistance. Kuzmenkov A.Yu, Trushin I.V, Avramenko A.A., et al. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. Given the high frequency of dysphonia reported with ALIS, this case highlights the potential severity of laryngeal toxicity, the importance of coordination of care for patients receiving inhaled antibiotics for chronic pulmonary disease, and the need for better insight into mechanisms of toxicity.Mensa J., Barberán J., Soriano A., et al. This is the first report directly describing vocal fold injury due to such therapy. Here, we describe a patient who experienced severe, acute-onset laryngitis while receiving ALIS for refractory M avium complex infection, prompting discontinuation of ALIS therapy. However, despite its efficacy, nearly one-half of patients in phase II and III trials experienced dysphonia as a treatment-associated adverse effect. Amikacin liposome inhalation suspension (ALIS) has emerged as a promising treatment for Mycobacterium avium complex infection refractory to oral antibiotics. Inhaled antibiotics have long been used for chronic lung infections, especially in patients with cystic fibrosis and increasingly for non-cystic fibrosis bronchiectasis.